Biotech firms tend to come on to SPACs’ radar when they still have some clinical work to complete to get to an approved medicine or device, but Avertix is ahead of that particular curve.
This week, we speak with Tim Moran, President and CEO of Avertix, and Ross Haghighat, CEO and CFO of BioPlus Acquisition Corp. (Nasdaq: BIOS). The two announced a $195 million dollar combination in May of this year.
Tim tells us how Avertix’s Guardian heart monitoring implant has performed in its initial commercial rollout, having already been approved by the FDA and for insurance reimbursements.
Ross meanwhile explains why being at that stage of the process was important for BioPlus’ criteria given the current market conditions and what further value streams could be unlocked by the Guardian device long term.
Give it a listen
Crown Reserve Acquisition Corp. I (NASDAQ:CRACU) has filed for a $150 million IPO to seek out a biotech deal with a team tied to one of the busiest names in SPACs recently. The new SPAC was filed as something of a pair with Quantumsphere Acquisition Corporation (NASDAQ:QUMSU), which was also underwritten by SPAC Advisory Partners...
FG Merger III Corp. has filed for a $150 million IPO to continue with the FG serial SPAC family with a larger vehicle focused on the financial services industry. The new SPAC is one of 16 SPACs that were filed in May and one of the four that overfunded its trust. FG Merger III is...
In our May 2025 corporate actions analysis, the SPAC market highlighted dependence on deadline extensions, with all votes involving sponsors seeking their third extension or beyond. While the total number of extension-related actions declined slightly from April, activity remained elevated compared to earlier months, reflecting the continued overhang from the 2021 SPAC wave. Extension Votes...
At the SPAC of Dawn The first week of June begins with just a pair of SPAC votes on the calendar, both of which are extensions, but this is a month that tends to host a fair amount of SPAC activity each year. Friday’s after-hours filing period may have provided a hint of this with...
Terms Tracker for the Week Ending May 30, 2025 Welcome to our weekly column where we discuss the findings from our IPO terms tracker based on the previous week’s pricings. May went out with a bang. Four more IPOs priced this week, bringing the monthly tally to 22 and the YTD total to 53. That...